Our Company
About Us
Leadership Team
Board of Directors
Advisory Board
Chemoprotection & ALRN-6924
Overview
Role of P53
Preclinical Research
Scientific Publications
Clinical Development
Investors & Media
Careers
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
Transforming the Experience of Chemotherapy for Patients
Learn More
What's New at Aileron
Press Releases
Aileron Therapeutics is a clinical stage company developing a novel medicine, ALRN-6924, to improve the outcomes and the quality of life of cancer patients.
Learn More
ALRN-6924 is administered prior to chemotherapy to protect healthy normal cells from negative side effects.
Learn More
Latest News
October 7, 2021
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
September 30, 2021
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
September 16, 2021
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
More News
